Healthcare
Live Price
Offline$536.59
-2.70% today
1Y Change
+92.56%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
United Therapeutics Corporation (UTHR) is a Healthcare stock with a market cap of $25.00B and listed on NASDAQ. The stock last traded around $536.59 and up 92.6% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +10.6%, EPS growth of +14.0%, a dividend yield of 0.0%. What stands out right now is revenue +10.6%, EPS +14.0%, free cash flow -3.7% with operating margin 46.9% and ROIC 15.9%. Valuation sits in the middle of the pack at P/E 18.9 and price/sales 7.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines UTHR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UTHR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UTHR Max Drawdown
-10.64%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UTHR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.7B
-13.0% YoY
FY Net Income
$475.8M
-34.6% YoY
Free Cash Flow
$477.4M
-28.1% YoY
Revenue Growth
+10.6%
EPS Growth
+14.0%
Gross Margin
87.9%
Net Margin
41.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 2.9B | 2.3B | 1.9B | 1.7B |
| Gross Profit | 2.8B | 2.6B | 2.1B | 1.8B | 1.6B |
| Operating Income | 1.5B | 1.4B | 1.2B | 980M | 556M |
| EBITDA | 1.8B | 1.7B | 1.4B | 1.0B | 737M |
| Net Income | 1.3B | 1.2B | 985M | 727M | 476M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.6B | 1.7B | 1.2B | 961M | 895M |
| Total Assets | 7.9B | 7.4B | 7.2B | 6.0B | 5.2B |
| Total Liabilities | 784M | 920M | 1.2B | 1.2B | 1.2B |
| Shareholder Equity | 7.1B | 6.4B | 6.0B | 4.8B | 4.0B |
| Total Debt | 0 | 300M | 700M | 800M | 800M |
| Net Debt | -1.6B | -1.4B | -508M | -161M | -95M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
598M
-25.5% YoY
Capital Expenditures
121M
+13.0% YoY
Free Cash Flow
477M
-28.1% YoY
Key ratios
Gross Margin
87.9%
Operating Margin
46.9%
Net Margin
41.9%
ROE
19.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.